Business Standard

Thursday, December 26, 2024 | 11:07 PM ISTEN Hindi

Notification Icon
userprofile IconSearch

Biocon Biologics gets capital injection of $150 mn from Goldman Sachs

Transaction values the IPO-bound biologics arm of Biocon at $3.94 billion

Kiran Mazumdar Shaw, Biocon CMD
Premium

Kiran Mazumdar-Shaw, executive chairperson, Biocon

Samreen Ahmad Bengaluru
Biopharmaceutical major Biocon has announced that the Board of its subsidiary Biocon Biologics has approved a capital injection of $150 million from global banking and investment firm Goldman Sachs.

According to the terms of the proposed agreement, Goldman Sachs will be issued Optionally Convertible Debentures at a post money equity valuation of $3.94 billion. The transaction is subject to customary approvals and conditions.

“We are extremely pleased to welcome a capital injection by Goldman Sachs at this inflection point of Biocon Biologics’ journey in its quest for global leadership in providing affordable access through Biosimilar drugs. This transaction is a

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in